How strong is the Roches pipeline

Mon, May 24, 2021, 11:38 a.m.

Roche: Two pieces of news on cancer pipeline

15.12.20 17:08
The shareholder

Kulmbach ( - Roche analysis of "Der Aktionär":

Marion Schlegel from the investor magazine "Der Aktionär" takes a close look at the profit participation certificate of the Swiss pharmaceutical company Roche AG (ISIN: CH0012032048, WKN: 855167, ticker symbol: RHO5, SIX Swiss Ex: ROG) in a current analysis.

The pharmaceutical giant could come up with two messages on its cancer pipeline on Tuesday. Roche will launch its mutation tests for patients with advanced breast cancer in several countries. In addition, Roche has received approval in Switzerland for its Rozlytrek therapy.

According to a press release on Tuesday, the Cobas test is an in-vitro diagnostic (IVD) test that was previously only available for research purposes. According to Roche, nearly two million women are diagnosed with breast cancer each year and an estimated half a million could have something called a PIK3CA mutation. If properly identified, some of these women could benefit from targeted therapy.

At the same time, Roche announced that the Swiss Medicines Institute (Swissmedic) had approved Rozlytrek for the treatment of adults and children from the age of twelve with solid tumors who had fused the gene for the neurotrophic tyrosine receptor kinase (NTRK).

On Monday, the Roche subsidiary Genentech also received approval for Ocrevus (ocrelizumab) from the US health authority FDA in the form of the shortened infusion duration. This shortens the treatment of multiple sclerosis patients to two hours, according to a statement on Monday evening.

Meanwhile, Roche is also pushing its efforts in the fight against corona and has recently entered into a partnership with Moderna. As part of the collaboration, the Elecsys anti-SARS-CoV-2 S antibody test will now be used in Moderna's mRNA 1273 vaccine research trials, according to Roche.

The Roche share is currently not in motion. THE SHAREHOLDER remains confident in the long term. The company is strongly positioned in the industry. Also not to be despised: Roche is a reliable dividend payer. The rate of return is currently 3.0 percent, according to Marion Schlegel from "Der Aktionär". (Analysis from December 15, 2020)

Please also note the information on the disclosure obligation in the event of conflicts of interest within the meaning of Directive 2014/57 / EU and corresponding EU regulations under the following link.